This article originally posted 29 May, 2009 and appeared in Issue 470
FDA Approves ACTOplus met(R) XR Tablets issue 470
FDA Approves ACTOplus met(R) XR Tablets for the Treatment of Type 2 Diabetes
Another "not new" drug, but new combination added to the arsenal for treating diabetes. Takeda Pharmaceuticals North America, Inc., has announced that the FDA approved an extended-release version of the combination medication ACTOplus met(R) (pioglitazone HCl and metformin HCl) as an adjunct to diet and exercise for the treatment of Type 2 diabetes. ACTOplus met(R) XR is the only oral antidiabetic fixed-dose combination medication available with the extended-release form of metformin to help improve glycemic control in a convenient, once-daily dosing option.
DISCLAIMER: The content of this Website is independent of the views of our advertisers and sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.
Copyright @ 1999-2012 Diabetes In Control, Inc.. All rights reserved.
Entries (RSS News)
